These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36697471)

  • 1. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
    Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
    Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 4. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 5. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.
    Huang CF; Liang PC; Tsai PC; Wei YJ; Huang CI; Wang CW; Jang TY; Yeh ML; Hsu PY; Hsieh MY; Lin YH; Dai CY; Chuang WL; Huang JF; Yu ML
    J Gastroenterol Hepatol; 2024 Jan; 39(1):193-201. PubMed ID: 37731071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
    Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
    Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
    Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
    Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
    Wu X; Li P; Mi YQ
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
    Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
    Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study.
    Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhao Y; Xu H; Li L; Tong N; Liu F
    Acta Diabetol; 2023 Feb; 60(2):225-233. PubMed ID: 36319797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
    Rodriguez-Duque JC; Calleja JL; Iruzubieta P; Hernández-Conde M; Rivas-Rivas C; Vera MI; Garcia MJ; Pascual M; Castro B; García-Blanco A; García-Nieto E; Olmo SC; Cagigal ML; Lopez-Montejo L; Fernández-Lamas T; Rasines L; Fortea JI; Vaque JP; Frias Y; Rivero M; Arias-Loste MT; Crespo J
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):406-414.e7. PubMed ID: 35124272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.
    Tan YW; Wang JM; Zhou XB
    World J Hepatol; 2023 Feb; 15(2):237-254. PubMed ID: 36926239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.